Moderna (MRNA) Return on Capital Employed (2019 - 2025)
Moderna (MRNA) has disclosed Return on Capital Employed for 7 consecutive years, with 0.3% as the latest value for Q4 2025.
- Quarterly Return on Capital Employed rose 1.0% to 0.3% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.3% through Dec 2025, up 1.0% year-over-year, with the annual reading at 0.27% for FY2025, 1.0% up from the prior year.
- Return on Capital Employed for Q4 2025 was 0.3% at Moderna, up from 0.33% in the prior quarter.
- The five-year high for Return on Capital Employed was 0.97% in Q4 2021, with the low at 0.34% in Q1 2024.
- Average Return on Capital Employed over 5 years is 0.16%, with a median of 0.07% recorded in 2023.
- The sharpest move saw Return on Capital Employed soared 145bps in 2021, then plummeted -85bps in 2023.
- Over 5 years, Return on Capital Employed stood at 0.97% in 2021, then crashed by -54bps to 0.45% in 2022, then crashed by -159bps to 0.27% in 2023, then dropped by -16bps to 0.31% in 2024, then rose by 3bps to 0.3% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.3%, 0.33%, and 0.3% for Q4 2025, Q3 2025, and Q2 2025 respectively.